Description
miRNA Research and Diagnostics Markets
This report, miRNA Research and Diagnostic Markets, focuses on the test product potential of microRNA. These pieces of RNA are seen as important regulators of gene expression; including growth, form, differentiation, and apoptosis. They serve myriad functions as regulator molecules in post-transcriptional gene silencing.
As the study details, a wide range of companies, both small biotechs and big pharmaceutical companies are committed to miRNA diagnostics.
As part of its coverage of this topic, this report includes the following:
- Discussion of miRNAs
- Upside for miRNA Diagnostic Technologies
- Downside Factors
- miRNAs and Neurological Disorders
- Prostate Cancer Screening and miRNAs
- miRNAs and Resistance to Anti-Cancer Drugs
- Theoretical Limitations
- Discussion of Patent Issues
- Interviews with Industry Experts
- Market Size
- miRNA and Metastatic Brain Lesions
As part of its coverage, the miRNA offerings and products in developments in the following companies are extensively reviewed:
- Illumina, Inc.
- Isis Pharmaceuticals
- Mello Biotechnology Inc.
- Microlin Bio
- MiRagen Therapeutics
- MiRNA Therapeutics
- Agilent Technologies
- Alnylam
- AMSBIO
- Applied Biosystems
- Asuragen
- DiamiR, LLC
- Novartis
- Pacific Edge Biotechnology
- Prolias Technologies
- Regulus Therapeutics
- Rosetta Genomics
- Santaris Pharma A/S
- Sirnaomics, Inc.
- Somagenics
- Diagnostics: Small RNA Assays and Biomarker Validation
- Tekmira Pharmaceuticals Corporation
- Thermadiag
- Thermo Fisher Scientific, Inc.
- Dicerna
- Eisai Biomarkers and Personalized Medicine
- Diagnostics
- Exiqon
- Genomic Health Inc.
- Gensignia
- GlaxoSmithKline Discovery and Molecular Toxicology
- Groove Biopharma (formerly Mirina)
- Hologic-Gen Probe Inc
Table of Contents
- Executive Summary
- Introduction
2.1. Junk DNA: Is There Such a Thing?
2.2. An Animated Debate
2.3. RNA Molecules Regulate Gene Expression
2.4. Types of Non-coding RNAs
2.5. Types of Small RNAs
- Current State of the Art
3.1. A Game Changer for Improved Diagnosis
3.1.1. MicroRNAs Are a Factor in Many Diseases
3.1.2. miRNAs and Neurological Disorders
3.1.3. miRNA and Metastatic Brain Lesions
3.1.4. miRNA Involvement in Cancers Is Widespread
3.1.5. Prostate Cancer Screening and miRNAs
3.1.6. Bladder Cancer and MicroRNAs in Urine
3.1.7. Colorectal Cancer
3.1.8. miRNAs and Resistance to Anti-Cancer Drugs
3.2. MicroRNA Nomenclature
3.3. MicroRNA Biogenesis
3.4. MicroRNA Cellular Functions
3.5. MicroRNA and Other Diseases
3.5.1. How Are microRNAs Linked to Disease?
3.5.2. Circulating microRNAs as Disease Markers
3.5.3. miRNAs and Tissue Injury
3.5.4. The Exosome
3.6. Exploring Therapeutic Applications
3.6.1. A Cautionary Tale: The History of Antibody Development
3.6.2. A Mixed Assessment of miRNA Therapeutic Potential
- Companies Developing microRNA Diagnostic Technologies
4.1. Agilent Technologies
4.2. Alnylam
4.3. AMSBIO
4.4. Applied Biosystems
4.5. Asuragen
4.6. DiamiR, LLC
4.7. Dicerna
4.8. Eisai Biomarkers and Personalized Medicine
4.9. Diagnostics
4.10. Exiqon
4.11. Genomic Health Inc.
4.12 Gensignia
4.13. GlaxoSmithKline Discovery and Molecular Toxicology
4.14. Groove Biopharma (formerly Mirina)
4.15. Hologic-Gen Probe Inc.
4.16. Illumina, Inc.
4.17. Isis Pharmaceuticals
4.18. Luminex (Millipore)
4.19. Mello Biotechnology Inc.
4.20. Microlin Bio
4.21. MiRagen Therapeutics
4.22. MiRNA Therapeutics
4.23. Novartis
4.24. Pacific Edge Biotechnology
4.25. Prolias Technologies
4.26 Regulus Therapeutics
4.26.1. Biomarker Studies of miRNAs through the Application of Microarrays
4.26.2. Clinical Trials
4.27. Rosetta Genomics
4.28. Santaris Pharma A/S
4.29. Sirnaomics, Inc.
4.30. Somagenics
4.30.1. Diagnostics: Small RNA Assays and Biomarker Validation
4.31. Tekmira Pharmaceuticals Corporation
4.32. Thermadiag
4.33. Thermo Fisher Scientific, Inc.
- Market Estimates and Forecasts
5.1. Long Range Estimate
5.2. Negative Forces That Can Affect the Outlook for miRNA Diagnostic Technologies
5.2.1. Theoretical Limitations of miRNAs
5.2.2. Resistance to miRNA R&D on the Part of Big Pharma
5.2.3. Lack of Basic Science Support by Government Funding Agencies
5.2.4. Patent Issues
5.3. Positive Factors That Move the Estimates
5.3.1. Inherent Shortcomings of Competitive Detection Systems
5.3.2. miRNA Technological Improvements
5.3.3. Current Studies Are Encouraging
5.3.4. Availability of Venture Capital
5.3.5. Specific Venture Capital Funding Opportunities
- Interviews with Industry Experts: Biomarkers
6.1. Anton Wellstein MD, PhD
6.2. Kai Wang, PhD
6.3. Samuil R. Umansky, MD, PhD
6.4. Dr. Mustafa Ozen
6.5. Dr. Nader Rifai
- The Future of miRNA-Based Diagnostics
7.1. Future Perspectives
7.2. Summary Recommendations
7.2.1. MicroRNA Compares Well with Competing Technologies
7.2.2. MicroRNA Assessment, Based on Its Own Performance
7.2.3. A Nuanced Endorsement
LIST OF EXHIBITS
- Executive Summary
Table 1.1: Forms of RNA and Abbreviations Explained
- Introduction
Table 2.1: Different Classes of RNA Molecules
- Current State of the Art
Figure 3.1: Increasing Number of Publications on miRNA
Figure 3.2: Results of microRNA Microarray Analysis
Table 3.1: Colorectal Cancer-Associated miRNA Markers
Figure 3.3: Method Validation: miRNAs Associated with Prostate Cancer
Table 3.2: Verification of Known Tissue-Specific Expression Patterns of Three mRNAs as Markers of Tissue Injury (miR-122, miR-133a and miR-124 Concentrations in Nine Rat Tissues)
Figure 3.4: Exosomes
Figure 3.5: Lagging Rate of Therapeutic Antibody Approval
- Companies Developing microRNA Diagnostic Technologies
Figure 4.1: Biogenesis of microRNAs (Gensignia)
Table 4.1: Regulus’ Clinical Map Initiative Outlines Current Status of Its microRNA Therapeutics Pipeline
Figure 4.2: Natural microRNA Precursors Marketed by Mello Biotech
Table 4.2: Summary of Data from Regulus miRNA Assessment Study
- Market Estimates and Forecasts
Table 5.1: miRNA Testing Market
Table 5.2: Major Providers of miRNA Tools and Services
Table 5.3: Top 10 Pharmaceutical Companies by R&D Expenditures in 2013
Figure 5.1: Funding Trends for Basic Research, 1950-2019
Table 5.4: Some Venture Capital Funding Opportunities
